AAN 2023 | Zavegepant nasal spray for the acute treatment of migraine with and without aura

Zavegepant is the only small-molecule CGRP receptor antagonist for intranasal administration approved by the FDA for the acute treatment of migraine. Timothy Smith, MD, RPh, FACP, StudyMetrix Research, St. Louis, MO, discusses a post-hoc subgroup analysis based on the pooled results of 2 randomized, double-blind clinical trials (NCT03872453, NCT04571060) comparing the efficacy of zavegepant nasal spray with placebo in the acute treatment of a single migraine attack. Subgroups reporting the presence or absence of aura were analyzed to compare the efficacy of zavegepant nasal spray with placebo in the acute treatment of migraine in participants with and without aura. The co-primary efficacy endpoints were pain freedom and freedom from most bothersome symptom (MBS) at 2 hours post-dose. Zavegepant was more effective than placebo on the co-primary endpoints and was effective and provided a rapid onset of action for the acute treatment of migraine regardless of the presence or absence of predose aura. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.